FP 100
Alternative Names: FP-100Latest Information Update: 28 Mar 2025
At a glance
- Originator Northeastern University
- Developer Flightpath Biosciences; Northeastern University
- Class Amides; Antibacterials; Antineoplastics; Furans; Phenols
- Mechanism of Action Peptidyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Bacterial infections; Colorectal cancer
- No development reported Leptospirosis; Lyme disease; Periodontal disorders
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Lyme-disease in USA (PO)
- 28 Mar 2025 No recent reports of development identified for research development in Leptospirosis in USA (PO)
- 28 Mar 2025 No recent reports of development identified for research development in Periodontal-disorders in USA (PO)